Research Context - Read Before Proceeding
All claims in this article reference preclinical (animal) or in vitro research unless explicitly stated otherwise. No compound discussed here is approved for human therapeutic use in South Africa unless specifically noted. Citations are provided for every material claim - see the References section below. This content is for scientific and educational purposes only. It does not constitute medical advice and must not be interpreted as a therapeutic recommendation. 18+ · Research use only.
Why You Cannot Understand This Stack Without Understanding the GH Axis First
Most explanations of CJC-1295 and Ipamorelin jump straight to the compounds. That is exactly backwards. The compounds only make sense in the context of how growth hormone secretion actually works, and most people have a significant misunderstanding of that biology.
Growth hormone is not secreted continuously. It is released in pulses - large, episodic bursts followed by periods of very low circulating GH. The largest pulses occur during the first few hours of deep sleep, in response to intense exercise, and during fasting. Between pulses, GH levels are low.
This pulsatile pattern is biologically important. The downstream effects of GH - protein synthesis, fat mobilisation, IGF-1 stimulation, tissue repair signalling - depend on having those high-amplitude pulses followed by low baseline periods. Continuous GH exposure, by contrast, downregulates receptor sensitivity over time. The pulse pattern is not a limitation of GH biology - it is how it is supposed to work.
Understanding this changes how you think about GH-targeted research. The goal is not to maximise circulating GH around the clock. The goal is to amplify the natural pulse pattern while preserving its structure.
---
## The Two Regulatory Signals You Need to Know
The hypothalamus controls GH secretion primarily through two opposing signals:
GHRH (Growth Hormone-Releasing Hormone): Stimulates pituitary somatotroph cells to produce and release GH. When GHRH arrives at the pituitary, it is the accelerator signal - prepare and release GH.
Somatostatin: Inhibits GH release. The brake. Somatostatin rises after meals, after carbohydrate ingestion, and in response to elevated cortisol. Its pulsatile alternation with GHRH creates the natural GH rhythm.
There is a third player: ghrelin, a peptide produced primarily in the stomach, which stimulates GH release through a completely separate receptor pathway - the growth hormone secretagogue receptor (GHS-R1a). Ghrelin is the hunger signal, but it is also an independent GH release trigger.
Two separate pathways - the GHRH pathway and the ghrelin/secretagogue pathway - both stimulate GH release but through different receptors. This creates an opportunity that CJC-1295 and Ipamorelin are specifically designed to exploit.
---
## CJC-1295: A Longer-Lasting GHRH Signal
Natural GHRH has a half-life of only a few minutes in circulation. The enzyme DPP-IV cleaves it rapidly. The result is that even a robust GHRH pulse from the hypothalamus produces only a brief signal window at the pituitary.
CJC-1295 is a synthetic GHRH analogue modified specifically to resist DPP-IV cleavage. This dramatically extends the duration of the GHRH-receptor signal without changing what that signal does.
There are two variants worth understanding:
CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF 1-29): Half-life of approximately 30 minutes. Acts like a longer-lasting GHRH pulse - it occupies the pituitary GHRH receptor for long enough to produce a meaningful GH release response, then clears. Preferred in combination research because it preserves the pulsatile character of GH release.
CJC-1295 with DAC (Drug Affinity Complex): Half-life of 6-8 days, achieved through albumin binding. Provides a sustained, near-continuous GHRH signal rather than a pulse. Different research applications, and different implications for the pulsatile pattern question discussed above.
Most combination research uses CJC-1295 without DAC because preserving pulse structure is considered important for physiological relevance.
---
## Ipamorelin: The Selective Secretagogue
Ipamorelin is a synthetic growth hormone secretagogue - a compound that stimulates GH release through the ghrelin receptor (GHS-R1a). It was developed specifically for its selectivity profile.
Earlier GH secretagogues (GHRP-2, GHRP-6) stimulated GH release effectively but also produced significant elevation of cortisol, prolactin, and ACTH. For research purposes, these off-target effects contaminate results - you cannot isolate GH-related effects from cortisol-related effects if cortisol is also elevated.
Ipamorelin was engineered to stimulate GH release through GHS-R1a with minimal effect on cortisol or prolactin. This selectivity makes it the most research-relevant GHS compound for combination protocols where you want to study GH-specific effects.
---
## Why Combining the Two Produces Superadditive GH Pulses
Here is the mechanistic insight that makes this combination more than just two compounds taken together:
The GHRH pathway and the ghrelin/secretagogue pathway are synergistic at the pituitary level. When both signals arrive simultaneously - GHRH occupying the GHRH receptor and Ipamorelin occupying GHS-R1a - the resulting GH pulse is substantially larger than either compound produces alone.
This has been directly documented in research. The combined response exceeds the sum of individual responses. It is superadditive, not merely additive.
The biological logic is straightforward: the GHRH signal primes pituitary somatotrophs for GH synthesis and release. The ghrelin/secretagogue signal activates a separate release pathway simultaneously. Both systems firing together produce a more robust pituitary response than either firing alone.
---
## The Somatostatin Timing Problem
Because somatostatin inhibits GH release, the timing of administration in research contexts matters for data validity. Somatostatin levels rise after meals, particularly after carbohydrate ingestion, and the elevated somatostatin tone will blunt the GH pulse you are trying to study.
Most research protocols are timed to avoid high somatostatin windows - specifically, administration during fasted states or well away from meals. This is not a safety consideration. It is a pharmacokinetic consideration that affects the quality and interpretability of your data. If you administer CJC-1295 and Ipamorelin after a high-carbohydrate meal and observe a blunted GH response, you have not learned anything about the compounds - you have studied somatostatin's effect on their action.
Control your variables. That is what separates research from anecdote.
18+ only. Research use only. Not for human consumption. Both compounds are on the WADA prohibited list for competitive athletes.